Amanote Research
Register
Sign In
Activity of PXD101, a Histone Deacetylase Inhibitor, in Preclinical Ovarian Cancer Studies
Molecular Cancer Therapeutics
- United States
doi 10.1158/1535-7163.mct-06-0111
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
August 1, 2006
Authors
X. Qian
Publisher
American Association for Cancer Research (AACR)
Related search
Preclinical Studies on Histone Deacetylase Inhibitors as Therapeutic Reagents for Endometrial and Ovarian Cancers
Future Oncology
Medicine
Cancer Research
Oncology
Preclinical Validation of AR42, a Novel Histone Deacetylase Inhibitor, as Treatment for Vestibular Schwannomas
Laryngoscope
Otorhinolaryngology
Preclinical Anti-Arthritic Study and Pharmacokinetic Properties of a Potent Histone Deacetylase Inhibitor MPT0G009
Cell Death and Disease
Molecular Neuroscience
Immunology
Cell Biology
Cancer Research
Cellular
Medicine
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells
Antioxidants and Redox Signaling
Cell Biology
Molecular Biology
Biochemistry
Clinical Biochemistry
Medicine
Physiology
A Chimeric SERM-Histone Deacetylase Inhibitor Approach to Breast Cancer Therapy
ChemMedChem
Organic Chemistry
Molecular Medicine
Pharmacology
Biochemistry
Toxicology
Drug Discovery
Pharmaceutics
A Novel Histone Deacetylase Inhibitor, CKD5, Has Potent Anti-Cancer Effects in Glioblastoma
Oncotarget
Oncology
Association of Histone Deacetylase Expression With Histology and Prognosis of Ovarian Cancer
Oncology Letters
Cancer Research
Oncology
Ovarian Cancer Animal Models for Preclinical Studies and Development of Ovarian Cancer Drugs
JURNAL ILMU KEFARMASIAN INDONESIA
